（文章来源：证券日报） 证券日报网讯 2月27日，科美诊断发布公告称，公司2025年实现营业总收入33267.86万元，同比下降 23.75%；归属于母公司所有者的净利润为4440.76万元，同比下降65.05%。 ...

科美诊断(688468.SH)发布2025年度业绩快报，报告期内，公司实现营业收入33,267.86万元，较上年同 期下降23.75%;实现归属于母公司所有者的净利润4,440.76万元，较上年同期下降65.05%。 报告期影响公司经营业绩的主要原因：(1)受体外诊断行业集采在全国范围内深度落地的阶段性影响， 公司主营产品价格承压，主营业务收入同比下降。(2)为增强核心竞争力，公司在产品创新方面保持较 高研发投入。(3)本期确认的政府补助等非经常性损益项目较上年同期减少。 ...

智通财经APP讯，科美诊断(688468.SH)发布2025年度业绩快报，报告期内，公司实现营业收入 33,267.86万元，较上年同期下降23.75%;实现归属于母公司所有者的净利润4,440.76万元，较上年同期下 降65.05%。 报告期影响公司经营业绩的主要原因：(1)受体外诊断行业集采在全国范围内深度落地的阶段性影响， 公司主营产品价格承压，主营业务收入同比下降。(2)为增强核心竞争力，公司在产品创新方面保持较 高研发投入。(3)本期确认的政府补助等非经常性损益项目较上年同期减少。 ...

科美诊断(688468)2月27日发布业绩快报，2025年实现营业总收入3.33亿元，同比下降23.75%；归母净利 润4440.76万元，同比下降65.05%；基本每股收益0.11元。报告期内，受体外诊断行业集采在全国范围 内深度落地的阶段性影响，公司主营产品价格承压，主营业务收入同比下降。为增强核心竞争力，公司 在产品创新方面保持较高研发投入。本期确认的政府补助等非经常性损益项目较上年同期减少。 ...

证券代码：688468 证券简称：科美诊断 公告编号：2026-002 科美诊断技术股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以科美诊断技术股份有限公司（以下简称"公司"）2025年年度的 定期报告为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（%） | | --- | --- | --- | --- | | 营业总收入 | 33,267.86 | 43,628.98 | -23.75 | | 营业利润 | 5,031.96 | 13,474.22 | -62.65 | | 利润总额 | 5,041.20 | 13,791.88 | -63.45 | | 归属于母公司所有者的净利润 | 4,440.76 | 12,707.47 | -65.05 | | 归属于母公司所有者的扣除非 经常性损益的净利润 | 2,814.5 ...

Group 1 - The company forecasts a net profit attributable to shareholders of the parent company for 2025 to be between RMB 40 million and RMB 48 million, representing a year-on-year decrease of 62.23% to 68.52% compared to the previous year [2] - The expected net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is projected to be between RMB 26 million and RMB 32 million, reflecting a year-on-year decline of 68.23% to 74.19% [2] - The previous year's net profit attributable to shareholders of the parent company was RMB 127.07 million, with a net profit after deducting non-recurring gains and losses of RMB 100.73 million [4] Group 2 - The decline in net profit is primarily due to the impact of centralized procurement in the in vitro diagnostics industry, which has pressured product prices and led to a decrease in main business revenue [6] - The company has maintained high R&D investment to enhance core competitiveness, which has contributed to the profit decline [7] - There has been a reduction in government subsidies and other non-recurring gains compared to the previous year [8]

Group 1 - The company, Kemei Diagnostics, announced an expected net profit attributable to shareholders for the year 2025 to be between RMB 40 million and RMB 48 million, representing a year-on-year decrease of 62.23% to 68.52% [2] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between RMB 26 million and RMB 32 million, reflecting a year-on-year decline of 68.23% to 74.19% [2]

Group 1 - The company, Kemei Diagnostics (688468.SH), announced an expected net profit attributable to shareholders of the parent company for the year 2025 to be between 40 million to 48 million yuan, which represents a year-on-year decrease of 62.23% to 68.52% compared to the previous year [1]

Core Viewpoint - Company expects a significant decrease in net profit for 2025, projecting between RMB 40 million to 48 million, which represents a year-on-year decline of 62.23% to 68.52 due to industry pressures [1] Financial Performance - The anticipated decline in net profit is primarily attributed to the impact of centralized procurement in the in vitro diagnostic industry, leading to price pressures on the company's main products and a decrease in main business revenue [1] - The company reported a reduction in non-recurring gains such as government subsidies compared to the previous year [1] Strategic Initiatives - To enhance core competitiveness, the company maintains a high level of investment in product innovation [1] - The company adheres to a long-term operational philosophy of serving human health through leading technology and innovative products, leveraging its proprietary LiCA® technology platform [1] - The company is focused on a dual-driven strategy of import substitution and clinical interactive innovation to create high-cost performance clinical products [1] Future Outlook - The company plans to continue its innovation-driven development path, strengthen cost management, actively respond to industry changes, and steadily advance the construction of core competitiveness to achieve sustainable high-quality development [1]

Financial Performance Forecast - The company expects a net profit attributable to shareholders of RMB 40 million to 48 million for the year 2025, representing a year-on-year decrease of 62.23% to 68.52% compared to the previous year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be RMB 26 million to 32 million, reflecting a year-on-year decline of 68.23% to 74.19%[3]. - In 2024, the company reported a total profit of RMB 137.92 million and a net profit attributable to shareholders of RMB 127.07 million[5]. - The financial data in the earnings forecast is preliminary and has not been audited by external accountants[10]. - Investors are advised to pay attention to investment risks as the final financial data will be disclosed in the audited annual report for 2025[11]. R&D and Innovation Strategy - The company maintains a high level of R&D investment to enhance core competitiveness despite the pressure on product prices due to industry-wide procurement policies[7]. - The company emphasizes a long-term operational philosophy focused on leading technology and innovative products to serve human health[9]. - The company is committed to a dual-driven strategy of import substitution and clinical interactive innovation using its proprietary LiCA® technology platform[9]. - The company aims to strengthen cost management and respond proactively to industry changes to build core competitiveness and achieve sustainable high-quality development[9]. Impact of External Factors - The reduction in government subsidies and other non-recurring gains compared to the previous year has impacted the financial performance[9].